All In Biotech

Drug Trial Radar · NCT06530251

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

A Phase Ib/II Study of AK112 in Combination Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC)

Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 280 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

280

Planned (sponsor's estimate)

Start

Sep 24, 2024

Primary completion

Jun 2026

Study completion Sep 2028

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Jul 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

There're 2 parts in this interventional study: 1. The goal of phase Ib trial is to evaluate the safety and tolerability of AK112 in combination therapies for the purpose of observing the incidence of dose limit toxicity (DLT) as well as the confirmation of maximum tolerable dose (MTD) in the treatment of advanced hepatocellular carcinoma (HCC), so as to determine the recommended phase 2 dose (RP2D) in the second part of the trial. 2. The goal of phase II trial is to evaluate the safety and efficacy of AK112 in combination therapy or monotherapy in the treatment of HCC compared to the combination of Sintilimab and Bevacizumab biosimilar.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • AK112Drug

    Following a predefined dose and date.

  • CadonilimabDrug

    Following a predefined dose and date.

  • AK127Drug

    Following a predefined dose and date.

  • AK130Drug

    Following a predefined dose and date.

  • Sintilimab InjectionDrug

    Following the local label direction.

  • Bevacizumab biosimilarDrug

    Following the local label direction.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with dose limiting toxicities (DLTs)Time frame: During the first three weeks.
  2. Number of subjects with adverse events (AEs)Time frame: From the time of informed consent signed through 90 days after the last dose of study drug.
  3. Objective Response Rate (ORR) (Phase II)Time frame: Up to approximately 2 years.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute,Shandong Cancer Hospital)

    Jinan, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.